Successful treatment of brain aspergillosis with voriconazole

被引:19
作者
Tattevin, P
Bruneel, F
Lellouche, F
de Broucker, T
Chevret, S
Wolff, M
Régnier, B
机构
[1] Pontchaillou Hosp, Infect Dis & Intens Care Unit, Rennes, France
[2] Andre Mignot Hosp, Intens Care Unit, Le Chesnay, France
[3] Henri Mondor Hosp, Intens Care Unit, Creteil, France
[4] Delafontaine Hosp, St Denis, France
[5] St Louis Hosp, Paris, France
[6] Bichat Claude Bernard Hosp, Intens Care Unit, Paris, France
关键词
Aspergillosis; azoles; brain aspergillosis; therapy; voriconazole;
D O I
10.1111/j.1469-0691.2004.00981.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Until recently, brain aspergillosis was almost always fatal, with a response rate to amphotericin B of < 10%. This study describes a retrospective analysis of eight consecutive cases of brain aspergillosis. All patients were immunosuppressed and five required mechanical ventilation. Antifungal treatment included amphotericin B (n = 7), itraconazole (n = 3), voriconazole (n = 2) and flucytosine (n = 1). Three (38%) patients survived following prolonged azole therapy after initial amphotericin B treatment, combined with a reduction in their immunosuppressive treatment. The prognosis of brain aspergillosis might be improved if immunosuppression could be reduced and prolonged oral azole therapy used.
引用
收藏
页码:928 / 931
页数:5
相关论文
共 20 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   Nosocomial cerebral aspergillosis: A report of 3 cases [J].
DarrasJoly, C ;
Veber, B ;
Bedos, JP ;
Gachot, B ;
Regnier, B ;
Wolff, M .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1996, 28 (03) :317-319
[3]   Burden of aspergillosis-related hospitalizations in the United States [J].
Dasbach, EJ ;
Davies, GM ;
Teutsch, SM .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (06) :1524-1528
[4]  
DeLone DR, 1999, AM J NEURORADIOL, V20, P1597
[5]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[6]   NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS [J].
DENNING, DW ;
LEE, JY ;
HOSTETLER, JS ;
PAPPAS, P ;
KAUFFMAN, CA ;
DEWSNUP, DH ;
GALGIANI, JN ;
GRAYBILL, JR ;
SUGAR, AM ;
CATANZARO, A ;
GALLIS, H ;
PERFECT, JR ;
DOCKERY, B ;
DISMUKES, WE ;
STEVENS, DA .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) :135-144
[7]   Therapeutic outcome in invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :608-615
[8]   Invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :781-803
[9]   Cerebellar aspergillosis: Case report and literature review [J].
Erdogan, E ;
Beyzadeoglu, M ;
Arpaci, F ;
Celasun, B .
NEUROSURGERY, 2002, 50 (04) :874-876
[10]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415